 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on KVD900, KalVistas lead drug program for oral on-demand treatment of hereditary angioedema HAE attacks, will be presented at the American Academy of Allergy, Asthma Immunology AAAI Annual Scientific Meeting 